FDA amends opioid action warning

Share this article:
The Food and Drug Administration will temporarily allow the continued production, marketing and distribution of one particular type of opioid, which is widely used to alleviate pain in terminally ill patients.

The action is in response to a March 30 warning that it issued to manufacturers to stop producing certain unapproved prescription opioids.  Concerns from palliative care patients and healthcare professionals prompted the FDA to amend the warning. They were concerned that the original order would cause a shortage of morphine sulfate oral solution.

The agency has determined that the 20 milligram dosage form of morphine sulfate oral solution is medically necessary and should remain on the market until an approved alternative becomes available.

Share this article:

More in News

Involving nursing assistants with decisions may result in higher quality, study finds

Empowering nursing assistants and family members of nursing home residents in decision-making results improved service, a new study finds.

Also in the news for July 28, 2014 . . .

Nursing home aide accused of choking a resident....Monitoring pulse after stroke may prevent another stroke...Slow walking speed may predict dementia

Site-neutral payments likely to move forward, experts believe

Site-neutral payments likely to move forward, experts believe

As the Centers for Medicare & Medicaid Services and the Medicare Payment Advisory Commission evaluate site-neutral payments, a new brief from Health Affairs and the Robert Wood Johnson Foundation explores ...